Suppr超能文献

罗氏诊断分析仪(模块化P型、Cobas Integra型)上的α2巨球蛋白免疫比浊法检测(达科西玛试剂)。在FibroTest-Actic-Test中的应用

[Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

作者信息

Piton A, Messous D, Imbert-Bismut F, Bergès J, Munteanu M, Poynard T, Hainque B

机构信息

Fédération de biochimie, hôpital de la Salpêtrière, Paris.

出版信息

Ann Biol Clin (Paris). 2005 Jul-Aug;63(4):385-95.

Abstract

BACKGROUND

Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into FibroTest-ActiTest-Fibro (FT-AT-Fibro) algorithm. More often than not, this assay is performed in immunonephelemetry. Progresses in the comprehension of fibrosis dynamics and better treatment efficacy follow-up will increase FT-AT-Fibro prescriptions. Despite efforts to standardize methods of enzymatic activity measure and proteins measure, we still observe important interlaboratory and intersystem variability.

AIM

The primary aim of the study is to validate immunoturbidimetric measure of A2M on Modular P and Cobas Integra analysers (Roche Diagnostics) in utility channel using DakoCytomation reagents in order to extend the analytical system range allowed to measure A2M. The secondary aim of the study is to verify transferability of the six FT-AT composants (A2M, haptoglobin, apolipoprotein A1, total bilirubin, GGT and ALT) to Roche Diagnostics equipment by comparing with results measured on the reference system.

RESULTS

A2M measures (n = 146) showed linearity, repetitiveness and were reproducible. Readjustments to adapt A2M measures were required. A corrector factor of 0.84 for Modular P and of 0.87 for Cobas Integra was introduced in order to readjust the immunoturbidimetric method to the immunonephelemetric method. The rationale of proposed corrector factors is based on the use of Dade Behring and DakoCytomation reagents (antisera and calibrant). Biologist vigilance is required to point out modifications or variations in reagents that could be done by the company. The six parameters results transferability from the reference system to Roche Diagnostics was demonstrated by statistic analysis. FT-AT showed excellent correlations to the reference system for Modular P and Cobas Integra analysers. In this study no difference more than 0.11 was recorded and only few subjects had differences between 0.05 and 0.10. Therefore this very low inter-analysers variability has no significant clinical impact.

CONCLUSION

This study showed that the analytical system made of Modular P, Cobas Integra, Roche Diagnostics and DakoCytomation reagents can be used for FibroTest-ActiTest-Fibro parameters assessment. Their statistical and clinical variability were acceptable compared to the reference system.

摘要

背景

自α2巨球蛋白(A2M)检测被引入FibroTest-ActiTest-Fibro(FT-AT-Fibro)算法以来,其应用再度兴起。通常,该检测采用免疫比浊法进行。随着对纤维化动态理解的进展以及对治疗效果更好的随访,FT-AT-Fibro检测的处方将会增加。尽管人们努力规范酶活性检测和蛋白质检测方法,但我们仍观察到实验室间和系统间存在显著差异。

目的

本研究的主要目的是在Modular P和Cobas Integra分析仪(罗氏诊断公司)的实用通道上,使用达科公司的试剂验证A2M的免疫比浊法检测,以扩大可用于检测A2M的分析系统范围。本研究的次要目的是通过与参考系统上测得的结果进行比较,验证FT-AT的六个组分(A2M、触珠蛋白、载脂蛋白A1、总胆红素、γ-谷氨酰转移酶和丙氨酸转氨酶)在罗氏诊断设备上的可转移性。

结果

A2M检测(n = 146)显示出线性、重复性且具有可重复性。需要进行调整以适应A2M检测。引入了Modular P的校正因子0.84和Cobas Integra的校正因子0.87,以便将免疫比浊法调整为免疫比浊法。所提议校正因子的原理基于使用达德拜林和达科公司的试剂(抗血清和校准品)。需要生物学家保持警惕,以指出公司可能对试剂进行的修改或变化。通过统计分析证明了六个参数结果从参考系统到罗氏诊断设备的可转移性。FT-AT在Modular P和Cobas Integra分析仪上与参考系统显示出极好的相关性。在本研究中,记录到的差异不超过0.11,只有少数受试者的差异在0.05至0.10之间。因此,这种极低的分析仪间差异没有显著的临床影响。

结论

本研究表明,由Modular P、Cobas Integra、罗氏诊断公司和达科公司试剂组成的分析系统可用于FibroTest-ActiTest-Fibro参数评估。与参考系统相比,它们的统计和临床差异是可以接受的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验